<DOC>
	<DOCNO>NCT01785992</DOCNO>
	<brief_summary>70 % breast cancer occur postmenopausal woman rely hormone oestrogen grow likely respond hormone treatment . This type treatment reduces amount oestrogen body , slow growth cancer stop altogether . One type hormone treatment , aromatase inhibitor ( AIs ) , work stop body make oestrogen . Currently , woman locally advance metastatic breast cancer control one class AI switch class AI . The reason cancer cell become resistant one class still sensitive class . However , oestrogen make body two pathway AIs block one pathway . A new drug call Irosustat reduce production oestrogen body block second pathway . This study investigate whether add Irosustat AI treatment i.e . block pathways time , reduce amount oestrogen body therefore control breast cancer well . 27 postmenopausal woman oestrogen receptor positive locally advanced metastatic breast cancer control current AI treatment recruit study 9 United Kingdom ( UK ) hospital . Eligible patient receive 40mg Irosustat daily addition AI progress . Patients receive Irosustat long control cancer side effect stop take treatment . Patients see monthly first 6 month every 3 month thereafter . Participating patient also give option take part exploratory part study donate tissue blood sample .</brief_summary>
	<brief_title>A Study Safety Effectiveness Irosustat When Added AI ER+ve Locally Advanced Metastatic Breast Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<criteria>1 . Written inform consent prior admission study . 2 . Aged ≥ 25 year age . 3 . Histologically confirm ER+ve primary metastatic breast cancer . 4 . Locally advanced metastatic breast cancer treat 1st line AI treatment either document objective response ( CR/PR ) disease stabilisation ( SD ) least 6 month prior disease progression . 5 . Postmenopausal define follow criterion : 1 . Amenorrhoea least 6 month prior study entry estradiol LH/FSH postmenopausal range local laboratory analysis whilst take 3rd generation AI screen phase study . 2 . Amenorrhoea combination treatment ovarian suppression ( e.g . goserelin ) AI case estradiol limit detection standard local laboratory assay screen phase study . 6 . ECOG performance status 0 2 . 7 . Measurable and/or evaluable site locally advance metastatic disease accurately assess CT/MRI scan baseline follow visit ( RECIST v1.1 ) . N.B Patients bone metastasis eligible provide evaluable metastasis site follow ( XRay MRI/CT scan ) . Patients establish bisphosphonate treatment least 3 month eligible entry trial allow continue bisphosphonate treatment . 8 . Adequate organ function define ( Haemoglobin ( Hb ) ≥ 9 g/dL ; Absolute Neutrophil Count ( ANC ) ≥ 1.5 x 109/L ; Platelet count ( Plts ) ≥ 100 ≥ 109/L ; White Blood Cell ( WBC ) ≥ 3.0 x 109/L ; Serum albumin ≤ 1.5 upper limit normal ( ULN ) ; Aspartate Aminotransferase ( AST ) Alanine Aminotransferase ( ALT ) ≤ 3 x ULN demonstrable liver metastasis ≤ 5 x ULN presence liver metastases ; alkaline phosphatase ( ALP ) ≤ 5 x ULN ; Total bilirubin ≤ 1.5 x ULN demonstrable liver metastasis ≤ 3 x ULN presence liver metastases ; Creatinine ≤ 1.5 x ULN creatinine clearance &gt; 50ml/min ) . 9 . Life expectancy ≥3 month . 1 . Human epidermal growth factor Receptor2 ( HER2 ) positive cancer . 2 . Discontinuation current AI therapy &gt; 21 day prior study entry . N.B If patient discontinue AI within period restart AI . This must continue least 7 day introduce IMP . Baseline investigation must perform timeframes related start IMP , AI . 3 . Rapidly progressive , lifethreatening metastasis , include follow : 1 . Patients active parenchymal brain leptomeningeal involvement 2 . Symptomatic lymphangitis carcinomatosis 3 . Extensive visceral metastasis require chemotherapy . 4 . Patients history another primary malignancy within 5 year prior start study treatment , except adequately treat basal squamous cell carcinoma skin , carcinoma site disease study . 5 . More one prior line chemotherapy locally advance metastatic disease . 6 . AI therapy give combination another endocrine agent exception GnRH agonist . 7 . Radiotherapy measurable lesion within 2 month treatment start . 8 . Systemic corticosteroid ≥ 15 day within last 4 week . 9 . Evidence uncontrolled active infection . 10 . Evidence significant medical condition laboratory finding , opinion Investigator , make undesirable patient participate trial . 11 . Concurrent therapy investigational agent . 12 . Concomitant use within 14 day prior commencement study treatment : 1 . Rifampicin CYP2C 3A inducer rifabutin , rifapentine , carbamazepine , phenobarbital , phenytoin St. John 's Wort 2 . Systemic carbonic anhydrase inhibitor . 13 . Any following cardiac criterion : 1 . Mean resting correct QT interval ( QTcf ) &gt; 450 m calculate Fridericia 's formula obtain 3 electrocardiogram ( ECGs ) 2 . Any clinically important abnormality rhythm , conduction morphology rest ECG e.g . complete leave bundle branch block , third degree heart block 3 . Any factor increase risk QTc prolongation risk arrhythmic event heart failure , hypokalaemia , congenital long QT syndrome , family history long QT syndrome unexplained sudden death 40 year age concomitant medication know prolong QT interval . 14 . Uncontrolled abnormality serum potassium , sodium , calcium ( correct ) phosphate magnesium level . 15 . Refractory nausea vomiting , chronic gastrointestinal disease , inability swallow formulate investigational medicinal product ( IMP ) previous significant bowel resection would preclude absorption Irosustat AI .</criteria>
	<gender>Female</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Oestrogen receptor</keyword>
	<keyword>Locally advanced</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>Sulfatase inhibitor</keyword>
</DOC>